The DOI matches its Crossref record.
Rapamycin Reverses Chronic Graft Vascular Disease in a Novel Cardiac Allograft Model
Abstract
Background —Chronic graft vascular disease (CGVD) in cardiac allografts has been defined as a slowly evolving vasculopathy unresponsive to conventional immunosuppression. We compared 4 rodent models of CGVD to evaluate the reproducibility of CGVD in heart allografts. Rapamycin (Rapa) and cyclosporine (CSA) were then used to treat CGVD. Methods and Results —Hearts were harvested and placed heterotopically into allogenic recipients. CGVD scores of PVG allografts from ACI recipients treated with CSA on days 1 through 10 were significantly elevated on day 90 (n=16) compared with other models (immunosuppression used): (1) Lewis to F344 recipients (CSA), (2) Brown Norway to Lewis (FK506), and (3) DA to Wistar-Firth (methylprednisolone, azathioprine, CSA). Although delayed (day 60 to 90) CSA treatment had no effect (n=6), delayed Rapa (3 mg · kg −1 · d −1 IP) reversed CGVD in PVG grafts (0.22±0.19 on day 90, n=6). ACI isografts showed no evidence of CGVD (n=6) at day 90. Immunohistochemistry of PVG grafts revealed perivascular infiltrates consisting of CD4 + T cells and limited numbers of macrophages persisting up to day 90. Flow cytometry demonstrated increased levels of anti-donor antibody at day 90, which was significantly inhibited by Rapa treatment. Conclusions —PVG grafts developed a significant increase in CGVD without evidence of ongoing myocardial rejection. This CGVD appeared to be mediated by both cellular and humoral mechanisms, given CD4 + perivascular infiltrates and increased levels of anti-donor antibody. The anti-CGVD effectiveness of Rapa during a period in which there was little myocardial cellular infiltrate supports a novel mechanism of effect such as smooth muscle or B-cell inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sousa, J. E., Costa, M. A., Abizaid, A., Abizaid, A. S., Feres, F., Pinto, I. M. F., Seixas, A. C., Staico, R., Mattos, L. A., Sousa, A. G. M. R., et al. (2001) · Circulation · doi:10.1161/01.cir.103.2.192 · Cited by 793
Rapamycin in transplantation: A review of the evidence
Saunders, R. N., Metcalfe, M. S., & Nicholson, M. L. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00460.x · Cited by 461
Bench to Bedside: The Development of Rapamycin and Its Application to Stent Restenosis
Marx, S. O., & Marks, A. R. (2001) · Circulation · doi:10.1161/01.cir.104.8.852 · Cited by 447
Use of Rapamycin Slows Progression of Cardiac Transplantation Vasculopathy
Mancini, D., Pinney, S., Burkhoff, D., LaManca, J., Itescu, S., Burke, E., Edwards, N., Oz, M., & Marks, A. R. (2003) · Circulation · doi:10.1161/01.cir.0000070421.38604.2b · Cited by 442
Roles of mTOR complexes in the kidney: implications for renal disease and transplantation
Fantus, D., Rogers, N. M., Grahammer, F., Huber, T. B., & Thomson, A. W. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.108 · Cited by 208
Metadata
- Authors
- Poston, R. S., Billingham, M., Hoyt, E. G., Pollard, J., Shorthouse, R., Morris, R. E., & Robbins, R. C.
- Venue
- Circulation
- Published
- 1999-07-06
- Volume
- 100
- Issue
- 1
- Pages
- 67-74
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2004533209
- Cited by
- 158
- References
- 0
- FWCI
- 14.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rapamycin Reverses Chronic Graft Vascular Disease in a Novel Cardiac Allograft Model. https://app.cochat.ai/papers/10.1161/01.cir.100.1.67
- The paper
- Poston, R. S., Billingham, M., Hoyt, E. G., Pollard, J., Shorthouse, R., Morris, R. E., & Robbins, R. C. (1999). Rapamycin Reverses Chronic Graft Vascular Disease in a Novel Cardiac Allograft Model. Circulation. https://doi.org/10.1161/01.cir.100.1.67
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.